{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:08Z","timestamp":1790686208131,"version":"4.1.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Cryptococcal infections are responsible for significant morbidity and mortality in immunocompromised patients. Reports of these infections in patients on small molecular kinase inhibitors have not been widely reported in clinical trials. We describe one case of cryptococcal meningoencephalitis and one case of cryptococcal pneumonia in two patients who were receiving ibrutinib for chronic lymphocytic leukemia. Despite different sites of cryptococcal infection, both patients had similar presentations of acute illness. Patient 1 was worked up for health care\u2013associated pneumonia, as well as acute sinusitis prior to the diagnosis of cryptococcal meningoencephalitis. He also had a more complex past medical history than patient 2. Patient 2 developed atrial fibrillation from ibrutinib prior to admission for presumed health care\u2013associated pneumonia. Cryptococcal antigen testing was done sooner in this patient due to patient receiving high-dose steroids for the treatment of underlying hemolytic anemia. We conclude that patients who develop acute illness while receiving ibrutinib should be considered for cryptococcal antigen testing.<\/jats:p>","DOI":"10.1177\/1078155217752078","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:27:13Z","timestamp":1516321633000},"page":"710-714","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia"],"prefix":"10.1177","volume":"25","author":[{"given":"Matthew","family":"Stankowicz","sequence":"first","affiliation":[{"name":"Southern Arizona VA Health Care System, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Banaszynski","sequence":"additional","affiliation":[{"name":"Southern Arizona VA Health Care System, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Crawford","sequence":"additional","affiliation":[{"name":"Southern Arizona VA Health Care System, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"bibr1-1078155217752078","unstructured":"Imbruvica\u00ae [package insert]. Horsham PA. Janssen Biotech, Inc. https:\/\/www.imbruvica.com\/docs\/librariesprovider7\/default-document-library\/prescribing_information.pdf (2017, accessed 24 October 2017)."},{"key":"bibr2-1078155217752078","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"bibr3-1078155217752078","first-page":"437","volume":"11","author":"Reisfeld-Zadok S","year":"2009","journal-title":"ISR Med Assoc J"},{"key":"bibr4-1078155217752078","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.717081"},{"key":"bibr5-1078155217752078","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2012.039"},{"key":"bibr6-1078155217752078","first-page":"4642831","volume":"2016","author":"Okamoto K","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"bibr7-1078155217752078","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw261"},{"key":"bibr8-1078155217752078","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1320710"},{"key":"bibr9-1078155217752078","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"bibr10-1078155217752078","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"bibr11-1078155217752078","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328322ffac"},{"key":"bibr12-1078155217752078","first-page":"61","volume":"124","author":"Pappas PG","year":"2013","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"bibr13-1078155217752078","doi-asserted-by":"crossref","unstructured":"Chamilos G, et\u00a0al. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways.\n                      Clin Infect Dis\n                      2017 [epub], doi: 10.1093\/cid\/cix687.","DOI":"10.1093\/cid\/cix687"},{"key":"bibr14-1078155217752078","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909050963"},{"key":"bibr15-1078155217752078","first-page":"1","author":"Williams AM","year":"2017","journal-title":"Leuk Lymph"},{"key":"bibr16-1078155217752078","doi-asserted-by":"crossref","unstructured":"Szymczak WA, et\u00a0al. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans infection.\n                      MBio\n                      2013; 4: pii:e00265-13.","DOI":"10.1128\/mBio.00265-13"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217752078","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217752078","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217752078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:55Z","timestamp":1777688275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217752078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/1078155217752078"],"URL":"https:\/\/doi.org\/10.1177\/1078155217752078","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]}}}